2.5mg weekly initiation, titrating every 4 weeks to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg
Maintenance / Spec
2.5mg weekly initiation, titrating every 4 weeks to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg
Titration Schedule & Escalation Milestones
Standard multi-phase escalation protocol designed to maximize target receptor engagement while minimizing acute gastrointestinal or cardiovascular desensitization.
Phase / Week
Target Dose
Administration Frequency
Weekly Total
Clinical Focus
Weeks 1–4 (Initiation)
0.25 mg – 0.5 mg
Weekly or 2x/Week
0.5 mg – 1.0 mg
Establish baseline receptor tolerability and assess glycemic response.
Weeks 5–8 (Step-Up)
1.0 mg – 2.0 mg
Weekly
1.0 mg – 2.0 mg
Begin steady-state plasma accumulation and therapeutic effect size.
Weeks 9–16 (Maintenance)
2.5 mg – 5.0 mg
Weekly
2.5 mg – 5.0 mg
Achieve maximal target receptor saturation and outcome progression.
Week 16+ (Optimization)
Maintenance or Taper
Weekly
As tolerated
Long-term physiological stabilization or planned washout cycle.
Higher concentration dilution matrix for concentrated micro-dosing and minimal injection fluid volume.
Target Dose (mg)
Target Dose (mcg)
Volume Required (mL)
Plunger Draw (U-100 Units)
0.25 mg
250 mcg
0.025 mL
2.5 Units
0.50 mg
500 mcg
0.050 mL
5.0 Units
1.00 mg
1,000 mcg
0.100 mL
10.0 Units
2.00 mg
2,000 mcg
0.200 mL
20.0 Units
4.00 mg
4,000 mcg
0.400 mL
40.0 Units
Pharmacokinetics & Elimination Half-Life
Tirzepatide exhibits an elimination half-life of approximately Approx. 5 days. Peak plasma concentrations (Cmax) are typically reached within 12 to 24 hours post-subcutaneous injection. Because steady-state equilibrium takes 4 to 5 half-lives to accumulate, abrupt dose jumps should be strictly avoided.
Step-by-Step Subcutaneous Injection Protocol
1. Swab the vial septum and the injection site (abdomen, outer thigh, or deltoid) with a 70% isopropyl alcohol prep pad.
2. Using a sterile U-100 insulin syringe (31G, 5/16"), invert the vial and draw the exact units calculated from the conversion table above.
3. Pinch a fold of subcutaneous adipose tissue at a 45-to-90-degree angle, insert the needle smoothly, and depress the plunger steadily over 3 to 5 seconds.
4. Rotate injection quadrants weekly to prevent localized lipodystrophy or tissue irritation.
Managing Missed Doses & Protocol Adjustments
If a scheduled weekly dose is missed by less than 3 days, administer the dose immediately upon remembering and maintain the original weekly schedule. If more than 4 days have elapsed, skip the missed dose and resume on the next regularly scheduled day. Never administer a double dose to compensate.
🔬 Peer-Reviewed References & Official Registries
Scientific literature and pharmacopeial standards underpinning this guide:
U.S. Food and Drug Administration (FDA Center for Drug Evaluation and Research)
Official FDA prescribing information, clinical pharmacology review, and pharmacovigilance documentation.
Key Analytical Takeaways
Begin with conservative initiation doses to establish baseline receptor tolerability.
Use 2.0mL BAC water per 10mg vial for easy 10 units = 0.5mg syringe measurement.
Rotate subcutaneous injection sites weekly to maintain optimal absorption across its Approx. 5 days half-life.
Frequently Asked Questions
❓ What is the best time of day to administer Tirzepatide?
Most protocols recommend morning administration on a consistent day of the week, either fasted or with a light meal depending on individual gastrointestinal sensitivity.
❓ How long does a reconstituted vial of Tirzepatide remain potent?
When stored in a sterile glass vial under continuous refrigeration (2°C to 8°C / 36°F to 46°F), reconstituted peptides maintain stability for 30 to 45 days.